Quintiles收购Novella Clinical

收购将提升昆泰的小型生物制药企业、肿瘤及医疗设备能力

北卡罗来纳州研究三角园--(美国商业资讯)--为走在全球客户不断变化的多元化需求的前面，昆泰(Quintiles)8月14日宣布签署一项旨在收购Novella Clinical (Novella)的协议。Novella是一家全方位服务型临床研究组织(CRO)，主要专注于新兴肿瘤客户以及医疗设备和诊断部门的客户。

昆泰临床开发部总裁Paula Brown Stafford说：“Novella团队所带来的专业知识与真知灼见将大大提升我们现有的能力，有助于让昆泰在竞争日益激烈的市场中进一步实现差异化。Novella对新兴企业的深入了解以及我们双方对品质、客户服务尤其是我们所服务的患者的共同承诺，使得这项收购交易非常适合两家组织。我们期待与Novella通力合作，利用双方公司的协同效益推动企业发展，同时继续满足客户需求。”

Novella心系客户，并根据其独特客户的运营需求打造了架构与临床研究方法，力求为这些特定的客户群提供最好的支持。加入昆泰后，Novella将能延续这一特别关注，与此同时，利用昆泰的规模和资源为其新老客户提供新的全球能力。

Novella总裁兼首席执行官Richard Staub说道：“我们非常高兴能有此机会加入业界的全球领导者昆泰。自15年前创办以来，Novella一直致力于通过提供个人关注与灵活性以及我们广泛的治疗经验来服务新兴公司。加入昆泰后，我们就能显著扩大我们服务的地理版图，同时继续恪守可让我们成为客户绝佳合作伙伴的价值观和经商理念。”

Novella总部设在北卡罗来纳州研究三角园，在北美和欧洲拥有800多位专业人士。该交易完成后，Novella将以昆泰旗下子公司Novella Clinical名义开展运营。该交易预计将于本季度晚些时候结束，但仍取决于标准与特别成交条件的达成。

该项交易的财务条款尚未披露。该交易预计不会对昆泰2013年每股盈余产生实质性影响。

关于昆泰

昆泰(Quintiles, NYSE: Q)是世界最大的生物制药开发和商业外包服务提供商，该公司的业务网络涵盖约100个国家，拥有员工27,000多名。市面上前50位的所有最畅销药品均由该公司帮助开发或实现商业化。昆泰凭借其服务的深度和广度，运用广泛的治疗、科学和分析专项技能，为生物制药和健康科学客户在日益复杂的环境中导航，帮助他们在交付更佳的医疗保健成果方面提升效率和功效。欲了解关于昆泰的更多信息，请访问：www.quintiles.com。

前瞻性陈述

本新闻稿可能包含1933年《证券法》第27A章和1934年《证券交易法》第21E章所界定含义之前瞻性陈述。此类前瞻性陈述反映的是昆泰公司的当前预期和期望的运营结果，所有这些都受到已知和未知的风险、不确定因素和其他因素的制约，这些因素可能导致昆泰公司的实际业绩、表现或成就、市场趋势，或行业业绩与此类前瞻性陈述中所表达或暗示的结果出现重大差异。因此，其中所包含的非历史事实的陈述可能为前瞻性陈述，并应按此进行评估。除上述之外，“预计”、“认为”、“估计”、“预期”、“打算”、“可能”、“计划”、“项目”、“应该”、“目标 ”等词汇及其否定形式和类似表达都是前瞻性陈述的标记。这些陈述受到风险、不确定性和假设因素的制约，包括该公司是否有能力完成及整合对Novella Clinical的拟议收购并实现预期目标，以及昆泰根据《证券法》第424(b)条于2013年5月9日向美国证券交易委员会(SEC)提交的日期为2013年5月8日的昆泰招股书中“风险因素”部分所描述的风险，而且此类风险可能会在昆泰定期向SEC提交的文件中不时更新，欲查看这些文件请访问SEC网站www.sec.gov。这些因素不应视为详尽无遗，而应与本新闻稿和昆泰向SEC提交文件中的其他警告性陈述一起阅读。除非法律要求，昆泰不承担更新任何此类前瞻性陈述以反映实际结果或变动对此类前瞻性信息影响的义务。

点击这里订阅有关昆泰的手机新闻。

免责声明：本公告之原文版本乃官方授权版本。译文仅供方便了解之用，烦请参照原文，原文版本乃唯一具法律效力之版本。

联系方式：

昆泰
Kevin Nash, 919-998-2514
媒体关系部
kevin.nash@quintiles.com
或
Greg Connors, 919-998-2000
企业发展部

2013年8月14日 Quintiles Transnational宣布签订协议，将收购Novella Clinical (Novella)，後者为专注新兴肿瘤客户、医疗器材、诊断业者的完整服务临床研究组织。


Quintiles to Acquire Novella Clinical

Acquisition bolsters Quintiles’ small biopharma, oncology and medical device capabilities

RESEARCH TRIANGLE PARK, N.C. – August 14, 2013 – To stay ahead of the diverse and evolving needs of its global customer base, Quintiles today announced it has signed an agreement to acquire Novella Clinical (Novella), a full-service clinical research organization (CRO) focused primarily on emerging oncology customers as well as those in the medical device and diagnostics sectors.

“The expertise and insight the Novella team brings will be a strong addition to our existing capabilities and help further differentiate Quintiles in an increasingly competitive marketplace,” said Paula Brown Stafford, President, Clinical Development at Quintiles. “Novella’s understanding of emerging companies, as well as our shared commitment to quality, customer service, and above all, the patients we ultimately serve, makes this acquisition a good fit for both organizations. We look forward to working collaboratively with Novella to leverage the synergies that exist between our companies to help drive business growth while continuing to meet the needs of our customers.”

Novella’s infrastructure and approach to clinical research were created with the operational needs of its unique customer base in mind, and constructed to best support these specific customer groups. By joining Quintiles, Novella will be able to continue this specialized focus while at the same time leveraging Quintiles’ scale and resources to provide new global capabilities to its existing and future customers.

“We are extremely excited about the opportunity to join Quintiles – the global leader in our industry,” said Richard Staub, President and CEO of Novella. “Since our founding fifteen years ago, Novella has been committed to serving emerging companies by offering personal attention and flexibility in addition to our extensive therapeutic experience. By joining Quintiles, we will be able to extend the geographic reach of our services exponentially while remaining committed to the values and business approach that makes us a great partner to our customers.”

Novella is headquartered in Research Triangle Park, N.C., and has more than 800 professionals located throughout North America and Europe. Upon completion of this transaction, Novella will operate as a unit within Quintiles and be known as “Novella Clinical, a Quintiles company.” The transaction, which is subject to standard and customary closing conditions, is expected to close later this quarter.

Financial terms of the transaction are not being disclosed. The acquisition is not expected to have a material impact on Quintiles’ 2013 earnings per share.

About Quintiles
Quintiles (NYSE: Q) is the world’s largest provider of biopharmaceutical development and commercial outsourcing services with a network of more than 27,000 employees conducting business in approximately 100 countries. We have helped develop or commercialize all of the top-50 best-selling drugs on the market. Quintiles applies the breadth and depth of our service offerings along with extensive therapeutic, scientific and analytics expertise to help our customers navigate an increasingly complex healthcare environment as they seek to improve efficiency and effectiveness in the delivery of better healthcare outcomes. To learn more about Quintiles, please visit www.quintiles.com.

- See more at: http://www.quintiles.com/library/press-releases/quintiles-to-acquire-novella-clinical/#sthash.7SpNddXn.dpuf